The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes
Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.
• Ability to provide informed consent for study participation
• Age ≥18 years and \<41 years old
• Singleton pregnancy at 24-34 weeks gestation
• Diagnosis of GDM via standard 1-step or 2-step criteria
• Treated with an insulin regimen that includes a RAA bolus of any type for breakfast, with a dose \<20 units
• Pre-pregnancy or first trimester body mass index (BMI) 25-45
• Investigator believes that the protocol can be safely conducted by the participant
• Able to read and speak English